BioMarin Pharmaceutical (BMRN) competitors & alternatives
Health Care · NASDAQ
BioMarin Pharmaceutical (BMRN)'s top competitors and alternatives — its most similar public companies — include Ultragenyx (RARE), Sarepta Therapeutics (SRPT), ROCKET PHARMACEUTICALS INC (RCKT), Alnylam Pharmaceuticals (ALNY), REGENXBIO INC (RGNX), ZEVRA THERAPEUTICS INC (ZVRA), BEAM THERAPEUTICS INC (BEAM), BridgeBio Pharma, Inc. (BBIO), ETON PHARMACEUTCIALS INC (ETON), CAPRICOR THERAPEUTICS INC (CAPR), EDITAS MEDICINE INC (EDIT) and Ionis Pharmaceuticals (IONS). These are BioMarin Pharmaceutical's closest public-company peers by sub-industry, sector and business themes and is informational only — not financial advice.
Top BMRN competitors & alternatives
-
UltragenyxRAREHealth Care
Ultragenyx is a biopharmaceutical company dedicated to developing and commercializing innovative therapies for serious, rare, and ultra-rare genetic diseases.
$27.65 (as of 2026-07-22) · market cap $2.8B
-
Sarepta TherapeuticsSRPTHealth Care
A biopharmaceutical leader in genetic medicine, specializing in innovative RNA-targeted therapies and gene treatments for Duchenne muscular dystrophy and rare…
$15.82 (as of 2026-07-22) · market cap $1.7B
-
ROCKET PHARMACEUTICALS INCRCKTHealth Care
Rocket Pharmaceuticals is a clinical-stage biotechnology company developing transformative gene therapies for rare, high-unmet-need genetic disorders.
$3.30 (as of 2026-07-22) · market cap $368M
-
Alnylam PharmaceuticalsALNYHealth Care
Alnylam is a global leader in RNA interference therapeutics, pioneering a new class of genetic medicines to treat rare and serious diseases.
$266.99 (as of 2026-07-22) · market cap $36.2B
-
REGENXBIO INCRGNXHealth Care
Clinical-stage gene therapy company using proprietary NAV vectors to deliver functional genes for rare genetic and retinal disorders through partnerships with…
$10.20 (as of 2026-07-22) · market cap $529M
-
ZEVRA THERAPEUTICS INCZVRAHealth Care
Zevra brings life-changing therapies to ultra-rare neurodegenerative and metabolic diseases, with FDA-approved MIPLYFFA for Niemann-Pick disease type C now…
$12.14 (as of 2026-07-22) · market cap $762M
-
BEAM THERAPEUTICS INCBEAMHealth Care
Beam Therapeutics is developing base editing medicines—a precision genetic cure approach—for serious inherited diseases like sickle cell disease and rare…
$26.64 (as of 2026-07-22) · market cap $2.7B
-
BridgeBio Pharma, Inc.BBIOHealth Care
BridgeBio translates genetic science into medicines for rare genetic diseases through a decentralized portfolio model, with an FDA-approved lead product in…
$82.66 (as of 2026-07-22) · market cap $16.2B
-
ETON PHARMACEUTCIALS INCETONHealth Care
Eton Pharmaceuticals develops and commercializes rare disease treatments, with a portfolio of ten marketed products and four late-stage candidates targeting…
$43.58 (as of 2026-07-22) · market cap $1.2B
-
CAPRICOR THERAPEUTICS INCCAPRHealth Care
Capricor is a clinical-stage biotech developing cell and exosome therapies for rare genetic disorders, with its lead candidate Deramiocel under FDA review for…
$18.91 (as of 2026-07-22) · market cap $1.1B
-
EDITAS MEDICINE INCEDITHealth Care
A pioneering CRISPR gene editing company developing in vivo therapies for genetic diseases, with lead candidate EDIT-401 targeting hyperlipidemia through LDL…
$2.78 (as of 2026-07-22) · market cap $421M
-
Ionis PharmaceuticalsIONSHealth Care
Pioneer in RNA-targeted antisense medicines with seven commercialized products and expanding late-stage pipeline across rare neurological and cardiometabolic…
$54.01 (as of 2026-07-22) · market cap $8.8B
Not quite? Describe exactly what you want →
Peers are BioMarin Pharmaceutical's closest public companies by shared sub-industry, sector and business themes. See the full profile: BioMarin Pharmaceutical (BMRN).
Last updated 2026-07-22.
Informational only — NOT financial advice. Company data is sourced from SEC EDGAR + Finnhub and shown with its as-of date.